Yahoo! My Yahoo! Mail | Donate to Hurricane Relief
Sign In
New User?Sign Up
Finance Home - Help
Welcome [Sign In] To track stocks & more, Register
Financial News
Enter symbol(s) BasicPerformanceReal-time MktDetailedChartResearchOptionsOrder Book Symbol Lookup
Press Release Source: MIV Therapeutics Inc.
MIV Therapeutics Reaffirms Leadership in Advanced Biocompatible Stent Coating Technology at International Conference
Wednesday September 21, 3:00 pm ET
Company Presents Next-Generation Coatings at 6th Pacific Rim Conference on Ceramics and Glass Technology
VANCOUVER, British Columbia--(BUSINESS WIRE)--Sept. 21, 2005--MIV Therapeutics, Inc. (OTCBB:MIVT - News), a developer of next-generation biocompatible stent coatings and drug delivery technologies, had an opportunity to increase awareness about its potentially revolutionary medical device coating technologies at a leading conference attracting bio-ceramics experts and other scientists from around the world, as part of the recent 6th Pacific Rim Conference on Ceramics and Glass Technology, held September 11-16, in Maui, Hawaii.
Dr. Tom Troczynski, Vice President of Coatings, delivered the Company's presentation, which focused on its novel bio-ceramic coating and drug-eluting technology innovations based on a porous material, hydroxyapatite (HAp), found in human bone and teeth.
"This conference attracted distinguished scientists, educators and innovators from all over the world in the broad field of ceramics and glass, which provided an excellent forum for intensive exchange of information about the latest discoveries and developments in the broad area of ceramic science," said Dr. Troczynski. "MIVT's presentation increased awareness about the unique biomedical advantages of our HAp coatings for stents and other important medical devices and therapeutic uses. It also reaffirmed our leadership position in the broad field of advanced thin film ceramic technology development, in particular development of ceramic technology for biomedical devices."
The MIVT presentation highlighted Company advancements in the development of the proprietary "Sol-Gel" aerosol-based technique for applying nano-sized, ultra-thin layers of HAp onto vascular stents, and electro-chemical and electro-phoretic methods of applying thicker layers for use as a novel drug-delivery coating. The presentation was called, "Deposition of Thin Ceramic Films on Complex Metallic Substrates - A Case Study of Hydroxyapatite Coatings on Coronary Stents."
MIVT develops novel solutions to coat implantable stents and other medical devices to increase device efficacy, safety and biocompatibility. The coatings, based on a natural HAp substance, has repeatedly been shown to perform better in preclinical animal studies than other coating substances sold on the market, for example those made of polymer.
The presentation was co-authored by MIVT's Arc Rajtar, Vice President of Operations, and scientists M. Lien, D. Smith, M. Tsui, as well as the University of British Columbia (UBC) scientists D. Hakimi, Q. Yang, and M. Keshmiri. UBC is an important strategic development and commercialization partner of MIVT.
About the Pacific Rim Conference on Ceramics and Glass Technology
The Bi-Annual Pacifc Rim Conference on Ceramics and Glass Technology attracts over 1,000 participants in development of leading edge ceramic technologies. Participants come from all over the Pacific Rim region, in addition to the United States, Canada, Australia, Mexico, and Europe.
Among the areas of advanced technology development covered in the expansive field of ceramic and glass sciences are:
Sign In
New User?Sign Up
Finance Home - Help
Welcome [Sign In] To track stocks & more, Register
Financial News
Enter symbol(s) BasicPerformanceReal-time MktDetailedChartResearchOptionsOrder Book Symbol Lookup
Press Release Source: MIV Therapeutics Inc.
MIV Therapeutics Reaffirms Leadership in Advanced Biocompatible Stent Coating Technology at International Conference
Wednesday September 21, 3:00 pm ET
Company Presents Next-Generation Coatings at 6th Pacific Rim Conference on Ceramics and Glass Technology
VANCOUVER, British Columbia--(BUSINESS WIRE)--Sept. 21, 2005--MIV Therapeutics, Inc. (OTCBB:MIVT - News), a developer of next-generation biocompatible stent coatings and drug delivery technologies, had an opportunity to increase awareness about its potentially revolutionary medical device coating technologies at a leading conference attracting bio-ceramics experts and other scientists from around the world, as part of the recent 6th Pacific Rim Conference on Ceramics and Glass Technology, held September 11-16, in Maui, Hawaii.
Dr. Tom Troczynski, Vice President of Coatings, delivered the Company's presentation, which focused on its novel bio-ceramic coating and drug-eluting technology innovations based on a porous material, hydroxyapatite (HAp), found in human bone and teeth.
"This conference attracted distinguished scientists, educators and innovators from all over the world in the broad field of ceramics and glass, which provided an excellent forum for intensive exchange of information about the latest discoveries and developments in the broad area of ceramic science," said Dr. Troczynski. "MIVT's presentation increased awareness about the unique biomedical advantages of our HAp coatings for stents and other important medical devices and therapeutic uses. It also reaffirmed our leadership position in the broad field of advanced thin film ceramic technology development, in particular development of ceramic technology for biomedical devices."
The MIVT presentation highlighted Company advancements in the development of the proprietary "Sol-Gel" aerosol-based technique for applying nano-sized, ultra-thin layers of HAp onto vascular stents, and electro-chemical and electro-phoretic methods of applying thicker layers for use as a novel drug-delivery coating. The presentation was called, "Deposition of Thin Ceramic Films on Complex Metallic Substrates - A Case Study of Hydroxyapatite Coatings on Coronary Stents."
MIVT develops novel solutions to coat implantable stents and other medical devices to increase device efficacy, safety and biocompatibility. The coatings, based on a natural HAp substance, has repeatedly been shown to perform better in preclinical animal studies than other coating substances sold on the market, for example those made of polymer.
The presentation was co-authored by MIVT's Arc Rajtar, Vice President of Operations, and scientists M. Lien, D. Smith, M. Tsui, as well as the University of British Columbia (UBC) scientists D. Hakimi, Q. Yang, and M. Keshmiri. UBC is an important strategic development and commercialization partner of MIVT.
About the Pacific Rim Conference on Ceramics and Glass Technology
The Bi-Annual Pacifc Rim Conference on Ceramics and Glass Technology attracts over 1,000 participants in development of leading edge ceramic technologies. Participants come from all over the Pacific Rim region, in addition to the United States, Canada, Australia, Mexico, and Europe.
Among the areas of advanced technology development covered in the expansive field of ceramic and glass sciences are: